Answers are grounded in this paper and cite their sources.
Randomized trial finds HR17031 improves HbA1c in type 2 diabetes, suggesting potential over its components.
To assess the efficacy and safety of HR17031, a fixed-ratio combination of basal insulin analogue (INS068) and GLP-1 receptor agonist (noiiglutide), versus its components alone in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug. This phase 2 multicentre trial randomised 455 patients with type 2 diabetes (HbA1c 7.5%-11.0% [58.0-97.0 mmol/mol]; previous metformin ± another oral antidiabetic drug) 2:2:1 to HR17031 (n = 183), INS068 (n = 182) or noiiglutide (n = 90). The primary endpoint was HbA1c change from baseline to week 26. HR17031 achieved a greater reduction in HbA1c than INS068 and noiiglutide (-2.4% [-26 mmol/mol] vs. -1.5% [-16 mmol/mol] and -1.7% [-19 mmol/mol]), indicating superiority for HR17031 over both INS068 and noiiglutide (least-squares mean difference = -0.9% [-10 mmol/mol] and -0.7% [-7 mmol/mol], respectively; both p < 0.0001). More patients reached HbA1c target <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) with HR17031 (<7.0%, 81.4%; ≤6.5%, 74.3%) than INS068 (47.8%; 26.4%) and noiiglutide (55.6%; 41.1%). HR17031 resulted in no weight gain in contrast to INS068 (-0.1 vs. 2.0 kg; p < 0.0001). Incidence of level 2/3 hypoglycaemia was similar with HR17031 (5.5%) and INS068 (4.4%), and lower with noiiglutide (1.1%). HR17031 demonstrated fewer instances of nausea (7.2%), diarrhoea (7.2%), and vomiting (2.8%) than noiiglutide (15.6%, 21.1%, and 20.0%). HR17031 is effective and well-tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: